SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is trending as traders speculate on a potential strategic partnership with Humana, fueled by recent job postings referencing Clover's software platform. Community sentiment remains mixed, balancing long-term optimism regarding the company's SaaS potential and Medicare Advantage growth against frustration over stagnant price action and perceived market manipulation.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on imminent positive guidance updates following the company's recent healthcare conference appearances and anticipation of upcoming Phase 2 NSCLC trial data. While the stock has seen significant momentum, community sentiment remains focused on potential institutional accumulation and the expectation that the company's solid tumor platform and clinical milestones will drive long-term value.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike shares are rallying sharply as traders react to record-breaking quarterly results and increased demand for AI-powered cybersecurity, with management emphasizing that AI-driven threats are accelerating the need for modern security platforms. While the stock's significant valuation premium continues to trigger debate among traders, sentiment is bolstered by bullish analyst price target hikes and positive read-throughs from industry conferences.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox shares are trending due to a sharp selloff following an earnings report that featured a revenue guidance withdrawal and concerns regarding monetization. While some traders are viewing the decline as an opportunity to buy the dip, others remain bearish, citing ongoing regulatory scrutiny, past controversies, and skepticism about the company's path to profitability.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as traders speculate on a potential recovery following a recent share price decline, with many discussing the company's pivot toward AI infrastructure and its upcoming re-entry into the Euro STOXX 50 index. While bulls highlight strategic partnerships and potential index-driven buying as catalysts for a rally, others express frustration with the stock's stagnant performance and ongoing concerns regarding market manipulation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Markets are volatile as traders weigh concerns over a potential slowdown in AI development against bullish rhetoric from Donald Trump, who continues to influence price action through social media. Discussion remains fragmented between bears highlighting macro headwinds like rising 10-year Treasury yields and oil prices, and bulls betting on liquidity-driven pumps ahead of the upcoming Federal Reserve meeting.

The Elmet Group Co. engages in the provision of precision-engineered components. The firm offers its products and solutions to aerospace, defense, industrial, medical, semiconductor, electronics, energy industry and also the government. It operates through the Critical Materials Components and Engineered Microwave Products business divisions. The company was founded on September 13, 2024 and is headquartered in Portland, ME.

Elmet Group Co. (The)

The Elmet Group

The Elmet Group is trending due to the company securing a massive investment and defense contract from the U.S. government to expand domestic tungsten production. Community sentiment is largely bullish, with traders emphasizing the stock's potential as a critical defense play, though some skeptics remain concerned about the financial structure and potential dilution.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is seeing increased attention as its Waymo unit launches fully driverless, public robotaxi services in Las Vegas. While some traders are focused on this autonomous expansion and AI infrastructure developments, others are debating broader concerns regarding elevated capital expenditures and market volatility.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders react to a sharp decline in AI and semiconductor stocks following calls from industry leaders to pace frontier AI development. While bearish sentiment is high due to these safety concerns and rising Treasury yields, market participants remain divided, with many debating the impact of the AI slowdown narrative versus the long-term infrastructure investment cycle.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne shares are trending as traders weigh its attractive valuation and AI-driven growth potential against broader sector volatility and lackluster price action compared to cybersecurity peers. The community remains divided between those viewing the stock as an undervalued takeover candidate with a strong balance sheet and those frustrated by the asset's underperformance relative to competitors like CrowdStrike and Palo Alto Networks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Protara Therapeutics (TARA) a New Buy Stock

Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.read more...

Equities Analysts Offer Predictions for TARA FY2028 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities research analysts at HC Wainwright raised their FY2028 EPS estimates for shares of Protara Therapeutics in a research note issued to investors on Wednesday, April 29th. HC Wainwright analyst A. Maldonado now expects that the company w...

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, f...

Stock Traders Buy Large Volume of Protara Therapeutics Call Options (NASDAQ:TARA)

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders bought 2,120 call options on the stock. This represents an...

Jacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 22,598 shares of Protara Therapeutics stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the sale...

Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 22,598 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total transaction of $118,865.48. Following the transaction, the...

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports...

Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 4,895,488 shares, an...

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Protara Therapeutics Inc

Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?

Equity

Bearish Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

TARA Protara Therapeutics Inc

Fundamentals

Latest TARA News